Castration-Resistant Prostate Cancer (CRPC) Guideline Amendment Webcast (2018)
To encourage consistent, high quality, evidence-based treatment of patients with Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC), the AUA and Urology Care Foundation has produced a series of online activities and educational resources for healthcare professionals, patients and caregivers. One of those such activities is this complimentary AUA Castration-Resistant Prostate Cancer Guideline Amendment webcast.
The goal of this complimentary webcast is to improve clinicians’ understanding of the 2018 update to the 2013 AUA Guidelines on CRPC. During this webinar, expert Faculty will:
- Explore the rigorous process used in the development of these evidence-based guidelines.
- Discuss new developments and future research needs for this topic.
- Showcase clinical scenarios in urological practice and the correct application of the new AUA guidelines in those instances.
This educational series is supported by an independent educational grant from:
- Astellas and Pfizer Inc.
- Advanced Practice Provider
- Non-Urologist (MD or DO)
- This activity may also be of interest to other clinicians and health care professionals involved in the treatment of patients impacted by CRPC
At the conclusion of this activity, participants will be able to:
- Identify the active agents and their mechanism of action in the management of nmCRPC.
- Analyze the evidence and outcomes on the treatment of CRPC as outlined in the AUA guidelines and subsequent amendments.
- Improve diagnostic and therapeutic decision making processes by illustrating the application of these guidelines in urological practice.
- Facilitate discussions with patients and caregivers regarding nmCRPC treatment options.
Welcome: Michael S. Cookson, MD, MMHC, FACS
M0 CRPC: Emerging Treatment Options - Matthew J. Resnick, MD, MPH, MMHC
Review of the AUA CRPC Guidelines: William K. Oh, MD
Michael S. Cookson, MD, MMHC, FACS: TesoRx Pharma LLC: Consultant or Advisor; Janssen Biotech, Inc.: Consultant or Advisor; MDxHealth: Consultant or Advisor; Bayer Healthcare Pharmaceuticals: Consultant or Advisor
William K. Oh, MD: sanofi-aventis: Consultant or Advisor; Bellicum Pharmaceuticals: Consultant or Advisor; Astellas: Consultant or Advisor; Bayer: Consultant or Advisor; Janssen: Consultant or Advisor; Tokai: Consultant or Advisor; Inovio: Consultant or Advisor; Churchill: Consultant or Advisor; Ferring: Consultant or Advisor; AstraZeneca: Consultant or Advisor
Matthew J. Resnick, MD, MPH, MMHC: MDx Heatlh: Consultant or Advisor; Genomic Health: Scientific Study or Trial
METHOD OF PARTICIPATION:
Learners will participate in this online educational activity by taking the pretest, viewing the webcast and completing the posttest and evaluation. To claim CME credit for this enduring material, learners must complete the posttest, passing with 80% accuracy and submit the program evaluation.
Estimated time to complete this activity: 1.00 hours
Release Date: September, 2018
Expiration Date: September, 2020
The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Urological Association designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
EVIDENCE BASED CONTENT:
It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA DISCLOSURE POLICY:
All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
RESOLUTION OF IDENTIFIED CONFLICT OF INTEREST:
All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
- Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
- Limit content to evidence with no recommendations
- Introduction of a debate format with an unbiased moderator (point-counterpoint)
- Inclusion of moderated panel discussion
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
- Divestiture of the relationship by faculty
OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES:
The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Non-Physician Participation